Overcoming the challenge of intracellular target access to transform the treatment of devastating diseases. Backed by 5AM Ventures.
About the role
This individual will be highly motivated and experienced clinical researcher interested in working on all phases of clinical development. Reporting to the Executive Director, Clinical Development, this individual will provide both a strategic lens and hands on support in designing, developing and implementing strategies to support clinical trials in Duchenne muscular dystrophy, utilizing Entrada’s unique EEV technology. Found on 1752vc Careers, the job board for startup and VC roles.
What they're looking for
- Ph.D., PharmD, MD, Nursing, or Clinical Master’s degree in a scientifically relevant field, with 6 + years of clinical development experience within the biotechnology or pharmaceutical industry
- Proven understanding of clinical development processes to serve as subject matter expert for phase 1-3 clinical studies
- Previous experience identifying trends and setting risk mitigation strategies in partnership with Medical teams within clinical studies
- Demonstrated experience in the design and execution of clinical trials and a strong understanding of GCP/ICH guidelines and regulatory expectations
- Experience in rare disease and/or neuromuscular disease is strongly preferred
- Skilled in Microsoft suite as well as innovative data review tools (ie. patient profiles, report generating tools)
More about this role
What's happening at Entrada Therapeutics? Entrada is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. Through proprietary and versatile approaches, Entrada is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. Our lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne muscular dystrophy (DMD) who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered with Vertex Pharmaceuticals to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1 (DM1).
2026 represents a catalyst-rich period for Entrada. We expect multiple clinical data readouts as we advance several DMD programs across the U.K., EU, and U.S. By year-end 2026, we anticipate four clinical-stage programs in our DMD franchise (ENTR-601-44, ENTR-601-45, ENTR-601-50, and ENTR-601-51). These programs are complemented by the ongoing clinical progress of our DM1 collaboration with Vertex...
Browse similar: Startup jobs · Boston